Stock Quote | 10/15/09 4:00 p.m. ET | Pricing delayed 20 minutes |
|
Recent News| Date | Title | | | 09/25/09 | Wyeth Receives Positive Opinion from European Regulators for its 13-valent Pneumococcal Candidate Vaccine for Infants and Young Children| COLLEGEVILLE, Pa., Sept. 25 /PRNewswire-FirstCall/ -- Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), announced today that the European Medicines Agency's (EMEA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for the company's pneumococcal conjugate vaccine, Prevenar 13* (Pneumococcal Polysaccharide Conjugate Vaccine [13-valent Adsorbed]). The CHMP recommends approval of Prevenar 13 for active immunization of children aged 6 weeks to 5 years for the ... |
|  | | 09/15/09 | Wyeth Presents Data from Five-Year Vertebral Fracture Prevention Study with Bazedoxifene| COLLEGEVILLE, Pa., Sept 15, 2009 /PRNewswire-FirstCall via COMTEX/ -- Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), announces findings from a placebo-controlled Phase 3 study of bazedoxifene 20 mg extended to five years, which indicated a significant reduction versus placebo in new vertebral fractures in postmenopausal women with osteoporosis. These and other data were presented at the American Society for Bone and Mineral Research (ASBMR) Annual Meeting in Denver, Colo. Bazedoxifene,... |
| | | 08/17/09 | Wyeth Announces Full Redemption of Floating Rate Convertible Senior Debentures Due 2024| MADISON, N.J., Aug. 17 /PRNewswire-FirstCall/ -- Wyeth (NYSE: WYE) (the
"Company") announced today that it has called for the full redemption of all
of its outstanding Wyeth Floating Rate Convertible Senior Debentures due 2024
(the "Convertible Debentures") on September 15, 2009. As of August 14, 2009,
there was $22,664,000 in aggregate principal amount of Convertible Debentures
outstanding.
Convertible Debentures will be redeemed by the Company at a cash purchase
price of $1,000... |
| | | 08/11/09 | Wyeth Provides Regulatory Update on Prevnar 13* in the United States| FDA extends review time by 90 days
COLLEGEVILLE, Pa., Aug. 11 /PRNewswire-FirstCall/ -- Wyeth
Pharmaceuticals, a division of Wyeth (NYSE: WYE), announced it received notice
that the action date for the U.S. Food and Drug Administration's (FDA) review
of the Biologics License Application (BLA) for Prevnar 13(TM), (Pneumococcal
13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]) has been extended
from September 30, 2009, to December 30, 2009. In response to an... |
| |
|
 |
Upcoming Events| There are currently no events scheduled. |
Transfer AgentStockholder Account Information: The Bank of New York Mellon is the transfer agent, registrar,
dividend disbursing agent and dividend reinvestment agent for the company. Stockholders of
record with questions about lost certificates, lost or missing dividend checks, or
notification of change of address should contact: Wyeth
c/o BNY Mellon Shareowner Services
P.O. Box 358015
Pittsburgh, PA 15252-8015 1-800-565-2067
(in the United States or Canada)
(201) 680-6578 (Outside the United States and Canada)
(800) 231-5469 (TDD for the hearing impaired) Internet address:
http://www.bnymellon.com/shareowner/isd Investor Hotline:
877-552-4744
» Click here to request information via mail. |
